Abstract
There is an increasing burden of circulating vaccine-derived polioviruses (cVDPVs) due to the continued use of oral poliovirus vaccine (OPV). However, the informativeness of routine OPV VP1 sequencing for the early identification of viruses carrying virulence-associated reversion mutations has not been directly evaluated in a controlled setting. We prospectively collected 15,331 stool samples to track OPV shedding from vaccinated children and their contacts for ten weeks following an immunization campaign in Veracruz State, Mexico and sequenced VP1 genes from 358 samples. We found that OPV was genetically unstable and evolves at an approximately clocklike rate that varies across serotypes and by vaccination status. Alarmingly, 28% (13/47) of OPV-1, 12% (14/117) OPV-2, and 91% (157/173) OPV-3 of Sabin-like viruses had ≥1 known reversion mutation. Our results suggest that current definitions of cVDPVs may exclude circulating virulent viruses that pose a public health risk and underscore the need for intensive surveillance following OPV use.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Information This project was funded by the National Institutes of Health 5R21AI148810 to YM. KSW was funded by a Thrasher Early Career Award and a Stanford Child Health Research Institute postdoctoral fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Stanford University Institutional Review Board (Protocol #31546), the Comite de Etica, Bioseguridad e Investigacion of the Instituto Nacional de Salud Publica (CI: 1260, No. 1581), and the Instituto Veracruzano para la Formacion e Investigacion en Salud (SESVER/IVEFIS//SIS/DIB/0109/02014, classification 15S).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interest Statement: All authors declare no competing interests.
Data Availability
The full-length VP1 sequences used in our study are publicly available on GenBank (Submission 2683280, 2683353, and 2683683). The references sequences used for sequence alignment are publicly available on GenBank AY184219, AY184220, AY184221). Multiple sequence alignments and metadata to reproduce figures and analyses are publicly available on GitHub (https://github.com/ksw9/opv-consensus).
